'Virus-cracking' molecules advance fight against hepatitis B

February 6, 2018, Indiana University
The shell, or capsid, that encapsulates the DNA of the hepatitis B virus, which is composed of 240 copies of the same protein. The green areas depict the structurally unique regions, which are found in a repeated arrangement across the surface of the shell. The small red areas reveal the sites where the molecule HAP binds to the virus. Credit: Christopher Schlicksup, Indiana University

Indiana University researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver failure and liver cancer.

It's estimated that 2 billion people worldwide have had a hepatitis B infection in their lifetime, with about 250 million—including 2 million Americans—living with chronic infection. Although a vaccine exists, there is no cure.

The study, published Jan. 29 in the journal eLife, explains how the structure of the hepatitis B virus changes when bound to an experimental drug. Members of this new class of antiviral drug are now in clinical trials.

"Our discovery suggests that this same drug could attack hepatitis B virus on multiple fronts—both preventing replication and killing new copies of the virus," said senior author Adam Zlotnick, a professor in the IU Bloomington College of Arts and Sciences' Department of Molecular and Cellular Biochemistry. "If we're smart, we can take advantage of the multiple ways this can work at the same time."

The research was led by Christopher Schlicksup, a graduate student in the department.

A virus reproduces by hijacking a host's cellular machinery to produce more of the virus. The majority of viruses protect their genetic material—DNA or RNA—inside a protein shell called a "capsid."

For the past 20 years, Zlotnick's lab has conducted research to stop viral infections by studying the physics of viruses, focusing on how capsids are formed.

"The reaction is a bit like throwing a deck of cards in the air to build the Taj Mahal—a highly complex structure seemingly emerging from chaos," Zlotnick said. His work helped discover a class of called core protein allosteric modulators, or CpAMs, that disrupt capsid protein assembly.

CpAM molecules attack viruses by causing their shells to assemble incorrectly, interrupting the life cycle of the virus. Previously, CpAMs were seen as only able to disrupt a virus during formation of the capsid, after which its DNA was protected inside a hard casing.

This new study finds the molecule can break apart this shell even after it has already assembled.

To make their discovery, IU scientists bound the CpAM to a chemical called TAMRA—a crimson-colored dye used in some red lipstick—to make it fluorescent and easier to detect in experiments. Using cryo-electron microscopy, they found the small CpAM molecule could make the large, soccer ball-shaped virus capsid bend and distort.

"The big implication is viral capsids aren't as impenetrable as previously thought," Zlotnick said. "The other implication, which may be even more important, is that if this type of interference works against hepatitis B virus, it might also work against other viruses.

"About half of known virus families have soccer ball-like capsids; examples include polio and herpes," he added. "This study may lead to better treatments against them since the mechanisms behind capsid disruption could lead to drugs against any of them."

Zlotnick also is the co-founder of Assembly Biosciences, a NASDAQ-listed company, which has CpAMs in . Although the molecule used in this study isn't one of the molecules under clinical trial, Zlotnick said the mechanism sheds light on the behavior of the experimental drugs. Next, Zlotnick hopes to conduct similar studies on the CpAMs under clinical trial.

Explore further: Zika virus protein mapped to speed search for cure

More information: Christopher John Schlicksup et al, Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids, eLife (2018). DOI: 10.7554/eLife.31473

Related Stories

Zika virus protein mapped to speed search for cure

March 27, 2017
A study published today shows how Indiana University scientists are speeding the path to new treatments for the Zika virus, an infectious disease linked to birth defects in infants in South and Central America and the United ...

Recommended for you

Drugs that stop mosquitoes catching malaria could help eradicate the disease

September 18, 2018
Researchers have identified compounds that could prevent malaria parasites from being able to infect mosquitoes, halting the spread of disease.

Vaccine opt-outs dropped slightly when California added more hurdles

September 18, 2018
In response to spiking rates of parents opting their children out of vaccinations that are required to enroll in school—and just before a huge outbreak of measles at Disneyland in 2014—California passed AB-2109. The law ...

New evidence of a preventative therapy for gout

September 17, 2018
Among patients with cardiovascular disease, it's a common complaint: a sudden, piercing pain, stiffness or tenderness in a joint that lasts for days at a time with all signs pointing to a gout attack. Gout and cardiovascular ...

"Atypical" virus discovered to be driver of certain kidney diseases

September 14, 2018
An international research team led by Wolfgang Weninger has discovered a previously unknown virus that acts as a "driver" for certain kidney diseases (interstitial nephropathy). This "atypical" virus, which the scientists ...

Flu shot rates in clinics drop as day progresses, but nudges help give them a boost

September 14, 2018
Primary care clinics experienced a significant decline in influenza vaccinations as the day progressed, researchers from Penn Medicine report in a new study published in JAMA Open Network. However, "nudging" clinical staff ...

Rare antibodies show scientists how to neutralize the many types of Ebola

September 13, 2018
Two new studies by scientists at Scripps Research are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.